The role of alpha-1-antitrypsin in the etiopathogenesis of chronic venous disease: A prospective clinical trial.

Autor:	Limandal HK; Department of Cardiovascular Surgery, 215289Erzurum Regional Education and Research Hospital, Erzurum, Turkey., Kayğın MA; Department of Cardiovascular Surgery, 215289Erzurum Regional Education and Research Hospital, Erzurum, Turkey., Özkaya AL; Department of Medical Biochemistry, 215289Erzurum Regional Education and Research Hospital, Erzurum, Turkey., Özkara T; Department of Cardiovascular Surgery, 215289Erzurum Regional Education and Research Hospital, Erzurum, Turkey., Diler MS; Department of Cardiovascular Surgery, 215289Erzurum Regional Education and Research Hospital, Erzurum, Turkey., Çüçen HI; Department of Cardiovascular Surgery, 215289Erzurum Regional Education and Research Hospital, Erzurum, Turkey., Yıldız Z; Department of Cardiovascular Surgery, 215289Erzurum Regional Education and Research Hospital, Erzurum, Turkey., Ergün S; Department of Pediatric Cardiovacscular Surgery, 215289Erzurum Regional Education and Research Hospital, Erzurum, Turkey., Dağ Ö; Department of Cardiovascular Surgery, 215289Erzurum Regional Education and Research Hospital, Erzurum, Turkey.
Jazyk:	angličtina
Zdroj:	Phlebology [Phlebology] 2023 Feb; Vol. 38 (1), pp. 16-21. Date of Electronic Publication: 2022 Nov 22.
DOI:	10.1177/02683555221141818
Abstrakt:	Objective: The study aimed to examine whether alpha-1-antitrypsin (AAT), an inhibitor of leukocyte esterase(LE), which damages the venous vessel wall, has a protective effect against chronic venous disease(CVD), and to examine the relationship between AAT levels and disease severity. Methods: Patients admitted with varicose vein disease and having reflux flow lasting longer than 0.5 s as determined by Doppler ultrasound were included. The informed consents were taken, and blood samples were obtained for complete blood count, C-reactive protein (CRP) level, and AAT level following anamnesis and physical examination. Clinical Etiologic Anatomic Pathologic (CEAP) classification was used to assess disease severity, and patients were divided into CEAP 1-5 groups accordingly. Results: A total of 87 patients were included in the study. There was no statistically significant difference between the groups in body weight, red blood cell counts, platelet counts, or neutrophil counts ( p = 0.117, p = 0.932, p = 0.177, and p = 0.177, respectively).CRP and AAT levels were higher in patients with a CEAP clinical score of 5 compared to the other groups ( p = 0.018, and p = 0.020, respectively). AAT levels were similar in the CEAP 1-3 group and decreased in the CEAP-4 group but increased again in the CEAP-5 group. The AAT level was 1.62 ± 0.3 g/L in the CEAP-1 group, 1.61 ± 0.21 g/L in the CEAP-2 group, 1.61 ± 0.27 g/L in the CEAP-3 group, 1.48 ± 0.28 g/L in the CEAP-4 group, and 1.94 ± 0.39 g/L in the CEAP-5 group. CRP levels and platelet counts were observed to affect AAT levels ( p = 0.10, p = 0.017, respectively). Conclusion: We believe that our hypothesis that low AAT levels play a role in the etiopathogenesis of CVD has been partially validated, at least in the CEAP-4 group. However, we believe that increased AAT levels in the CEAP-5 group may be a reactive increase in increased LE levels due to higher CRP levels of this group.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu